- Home
- OSUR vs AVIR Comparison
OSUR vs AVIR Comparison
Compare OSUR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- AVIR
- Stock Information
- Founded
- OSUR 2000
- AVIR 2012
- Country
- OSUR United States
- AVIR United States
- Employees
- OSUR N/A
- AVIR N/A
- Industry
- OSUR Medical/Dental Instruments
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- OSUR Health Care
- AVIR Health Care
- Exchange
- OSUR Nasdaq
- AVIR Nasdaq
- Market Cap
- OSUR 334.1M
- AVIR 290.4M
- IPO Year
- OSUR 1986
- AVIR 2020
- Fundamental
- Price
- OSUR $4.13
- AVIR $3.56
- Analyst Decision
- OSUR Buy
- AVIR Hold
- Analyst Count
- OSUR 3
- AVIR 1
- Target Price
- OSUR $6.67
- AVIR $6.88
- AVG Volume (30 Days)
- OSUR 459.6K
- AVIR 152.3K
- Earning Date
- OSUR 11-05-2024
- AVIR 11-06-2024
- Dividend Yield
- OSUR N/A
- AVIR N/A
- EPS Growth
- OSUR N/A
- AVIR N/A
- EPS
- OSUR 0.36
- AVIR N/A
- Revenue
- OSUR $273,535,000.00
- AVIR N/A
- Revenue This Year
- OSUR N/A
- AVIR N/A
- Revenue Next Year
- OSUR N/A
- AVIR N/A
- P/E Ratio
- OSUR $11.35
- AVIR N/A
- Revenue Growth
- OSUR N/A
- AVIR N/A
- 52 Week Low
- OSUR $3.92
- AVIR $2.77
- 52 Week High
- OSUR $8.45
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- OSUR 45.49
- AVIR 49.38
- Support Level
- OSUR $4.00
- AVIR $3.31
- Resistance Level
- OSUR $4.16
- AVIR $3.86
- Average True Range (ATR)
- OSUR 0.08
- AVIR 0.12
- MACD
- OSUR 0.01
- AVIR 0.03
- Stochastic Oscillator
- OSUR 57.89
- AVIR 46.90
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).